Payment overview · 2025
General Payments
$273.71
13 reported records · 10 companies
Healthcare provider profile · identity verified
Denice Smith, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROCK FALLS, IL · NPI 1134171085
Verified facts
What the public records show
CMS Open Payments records show Denice Smith, MD received $273.71 in general payments during 2025 across 13 reported records.
Axsome Therapeutics, Inc. accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zenpep by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vivitrol by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $86.54 | 31.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.27 | 13.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.11 | 12.5% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $19.64 | 7.2% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $19.44 | 7.1% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $17.51 | 6.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.84 | 5.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.90 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.23 | 5.2% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $14.23 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $273.71 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $86.54 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $19.64 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 620 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 472 | 111 |
| Lisinopril | Lisinopril | 397 | 119 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 308 | 83 |
| Metformin Hcl | Metformin Hcl | 291 | 80 |
| Gabapentin | Gabapentin | 263 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 58 |
| Glipizide | Glipizide | 216 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 48 |
| Sertraline Hcl | Sertraline Hcl | 160 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 31 |
| Simvastatin | Simvastatin | 141 | 38 |
| Potassium Chloride | Potassium Chloride | 137 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 131 | 35 |
| Omeprazole | Omeprazole | 127 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 119 | 25 |
| Montelukast Sodium | Montelukast Sodium | 114 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 34 |
| Ezetimibe | Ezetimibe | 108 | 39 |
| Furosemide | Furosemide | 108 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 20 |
| Trulicity | Dulaglutide | 104 | 22 |
| Buspirone Hcl | Buspirone Hcl | 100 | 28 |
| Famotidine | Famotidine | 96 | 29 |
| Losartan Potassium | Losartan Potassium | 94 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 28 |
| Eliquis | Apixaban | 91 | 25 |
| Meloxicam | Meloxicam | 90 | 28 |
| Trazodone Hcl | Trazodone Hcl | 88 | 31 |
| Jardiance | Empagliflozin | 82 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 12 |
| Ozempic | Semaglutide | 76 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 18 |
| Alendronate Sodium | Alendronate Sodium | 64 | 22 |
| Mirtazapine | Mirtazapine | 64 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 25 |
| Clonidine Hcl | Clonidine Hcl | 63 | 17 |
| Lovastatin | Lovastatin | 63 | 18 |
| Alprazolam | Alprazolam | 62 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Spironolactone | Spironolactone | 58 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 14 |
| Farxiga | Dapagliflozin Propanediol | 54 | 11 |
| Prednisone | Prednisone | 54 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 16 |
| Ibuprofen | Ibuprofen | 50 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 48 | 13 |
| Carvedilol | Carvedilol | 47 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 15 |
| Tramadol Hcl | Tramadol Hcl | 44 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | 11 |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 11 |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | 12 |
| Nystatin | Nystatin | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Ubrelvy | Ubrogepant | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 19 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Vivitrol | Naltrexone Microspheres | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $273.71 · 13 records | Axsome Therapeutics, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, Auvelity, BRIXADI, CAPLYTA, INVEGA SUSTENNA, LYBALVI, NEXPLANON, SLYND, The Cologuard Plus Collection Kit, ZENPEP | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Zenpep play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error